Published in BioCentury, March 31, 2014
When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months — early stage, European drug development companies. The recent exits also highlight the firm’s decision to focus on companies ripe for trade sales and to diversify its portfolio through a trio of complementary funds. Since its beginnings in 1988, LSP has raised a total of $1 billion in eight funds and has invested in 75 private companies. There have been 18 IPOs and 25 trade sales across seven venture funds. Click here for the full Biocentury article
« back to overview
When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months — early stage, European drug development companies. The recent exits also highlight the firm’s decision to focus on companies ripe for trade sales and to diversify its portfolio through a trio of complementary funds. Since its beginnings in 1988, LSP has raised a total of $1 billion in eight funds and has invested in 75 private companies. There have been 18 IPOs and 25 trade sales across seven venture funds. Click here for the full Biocentury article